In preclinical models, PARP inhibitors showed synergistic activity with immune checkpoint inhibitors,32 which has led to several ongoing clinical trials combining these two promising new classes of cancer therapeutic agents (see e.g. clinical trial NCT02657889). This evidence concerns the gene PARP1 and cancer.